Information Provided By:
Fly News Breaks for January 3, 2020
Jan 3, 2020 | 07:42 EDT
Cantor Fitzgerald analyst Eliana Merle said she views Incyte's (INCY) announcement that itacitinib missed its Phase 3 endpoint in GRAVITAS-301 in treatment-naive acute graft-versus-host disease, or GVHD, as a positive for Kadmon (KDMN), whose lead asset, KD025, may now face less commercial competition. She had assumed itacitinib competition in her base case, so she sees this setback as providing "meaningful commercial upside" for KD025, Merle tells investors. The analyst, who continues to see the cGHVD market opportunity as underappreciated for Kadmon and model $500M in U.S. peak sales, keeps an Overweight rating and $10 price target on Kadmon shares.
News For KDMN;INCY From the Last 2 Days
Feb 16, 2020 | 15:57 EST
Specialty Pharma Analyst Chen, Biotech Analysts Young & Merle, along with Key Opinion Leaders Dr. Goldberg, Skin Laser & Surgery Specialists of NY & NJ and Dr. Weinberg, Forest Hills Dermatology Group, discuss the competitive landscape in atopic dermatitis at a Group Luncheon Meeting being held at Cantor's New York offices on February 24 at 12 pm.